Benefit of ECMO in Resuscitation from Refractory V Fib Cardiac Arrest
The dawn of a new era
Although ventricular tachycardia/ventricular fibrillation (v tach/v fib) constitutes only 25-35% of all cardiac arrests, more than 80% of all cardiac arrest survivors with favorable neurological function present with v tach/v fib.1,2 (See Figure 1.) Despite that, only one third (approximately 30%) of patients presenting initially with v tach/v fib survive to hospital discharge with good neurological function.
Compared to the other presenting rhythms (asystole and pulseless electrical activity) v tach/v fib is associated with the highest survival and stands out as the most important positive p...
Source: JEMS Patient Care - December 1, 2017 Category: Emergency Medicine Authors: Demetris Yannopoulos, MD Tags: Patient Care Cardiac & Resuscitation Source Type: news
Delayed onset of atrial fibrillation and ventricular tachycardia after an automobile lightning strike - Drigalla D, Essler SE, Stone CK.
BACKGROUND: Lightning strike is a rare medical emergency. The primary cause of death in lightning strike victims is immediate cardiac arrest. The mortality rate from lightning exposure can be as high as 30%, with up to 70% of patients left with significant... (Source: SafetyLit)
Source: SafetyLit - September 13, 2017 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news
Is BioSig for Real This Time With Its Pure EP?
A couple years ago, BioSig Technologies, Inc. was poised to apply for FDA clearance to market its technology to improve treatment of atrial fibrillation and ventricular tachycardia. Then its scientific advisors advised the Minneapolis company to put more work into that technology, a hardware-software combination designed to present clearer signals during electrophysiology studies and catheter ablation.
The technology, Pure EP, is designed to cut through the background noise of the lab and its equipment during cardiac recordings, enabling physicians to target and neutralize the areas of the heart that are causing atrial fi...
Source: MDDI - September 7, 2017 Category: Medical Devices Authors: Nancy Crotti Tags: MD & M Minneapolis R Software Source Type: news
Milestone Pharmaceuticals Closes $55 Million Series C Financing
Proceeds to Fund Etripamil Phase 3 Development and Pre-Launch Market Development
MONTREAL, August 1, 2017 -- (Healthcare Sales & Marketing Network) -- Milestone Pharmaceuticals Montreal, Canada, Inc., a clinical stage cardiovascular company, today anno... Biopharmaceuticals, Venture Capital, Personnel Milestone Pharmaceuticals, etripamil, supra-ventricular tachycardia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 1, 2017 Category: Pharmaceuticals Source Type: news
Ablation of Ventricular Tachycardia in Patients With MitraClip Ablation of Ventricular Tachycardia in Patients With MitraClip
Patients with mitral regurgitation are increasingly being treated with a MitraClip device. Is it feasible and safe to perform catheter ablation for ventricular tachycardia in these patients?Journal of Cardiovascular Electrophysiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 29, 2017 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Chest Pain Drug Decreases Common Arrhythmias
A drug approved to treat chest pain reduces the incidence of a common arrhythmia called ventricular tachycardia in patients with an implantable cardioverter defibrillator, according to a study presented today at the Heart Rhythm Society ’s annual meeting. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - May 12, 2017 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news
Add-on Tx Cuts Exercise-Induced Arrhythmia in Genetic CPVT
(MedPage Today) -- Flecainide helps in catecholaminergic polymorphic ventricular tachycardia (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 11, 2017 Category: Cardiology Source Type: news
HRS 2017: Two-year registry data on Boston Scientific ’ s S-ICD
Data from a long-term post-approval registry study of the S-ICD subcutaneous pacemaker made by Boston Scientific (NYSE:BSX) showed high successful implantation rates and “acceptable” short-term complication rates, researchers said today at the annual Heart Rhythm Society conference in Chicago.
The study looked at data from 1,637 S-ICD patients who met the criteria for implantable cardioverter defibrillator implantation, passed at least 1 electrocardiogram screening vector and had a life expectancy of more than 1 year. The mean follow-up time was 2 years and the study plans to follow patients out to 5 years.
...
Source: Mass Device - May 11, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Boston Scientific Cardiac Rhythm Management hrs2017 Source Type: news
Zoll Medical wins Health Canada nod for next-gen AEDs
Zoll Medical said this week it won approval from Health Canada for its Zoll AED 3 and Zoll AED 3 BLS automated external defibrillators and launched them in the region.
Both newly-cleared AEDs provide real-time feedback to communicate appropriate timing for effective CPR through audible and visual prompts, which the Chelmsford, Mass.-based company said can be critical to a patient’s survival.
“We are extremely excited to add the Zoll AED 3 and the Zoll AED 3 BLS to our portfolio of automated external defibrillators. With the addition of these new devices, we are able to offer our public access and BLS customer...
Source: Mass Device - March 23, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Regulatory/Compliance Resuscitation Zoll Medical Corp. Source Type: news
BioSig inks strategic partnership deal with Mayo Clinic
BioSig Technologies (OTCQB: BSGM) said today it inked a 10-year strategic agreement with the Mayo Clinic to develop advanced clinical features and applications for its Pure EP system.
The new agreement expands on an earlier Advanced Clinical Research Program between BioSig and the Mayo clinic signed last March.
“We are pleased to strengthen and broaden our relationship with Mayo Clinic and Mayo Ventures to grow our innovation capabilities and deliver superior medical technology,” founder & exec chair Kenneth Londoner said in a prepared statement.
BioSig said it will work with Dr. Samuel Asirvatham and Dr...
Source: Mass Device - March 17, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Research & Development BioSig Technologies Source Type: news
Milestone Pharmaceuticals Announces Appointment of Joseph G. Oliveto as Chief Executive Officer
MONTREAL, March 7, 2017 -- (Healthcare Sales & Marketing Network) -- Milestone Pharmaceuticals USA, Inc., a clinical stage cardiovascular company, today announced the appointment of Joseph G. Oliveto as President and Chief Executive Officer, effective imm... Biopharmaceuticals, Cardiology, Personnel Milestone Pharmaceuticals, etripamil, paroxysmal supra-ventricular tachycardia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 7, 2017 Category: Pharmaceuticals Source Type: news
Francesca ’s story: Beating a heart tumor
Although her parents were warned she might not breathe when she was born, the moment Francesca Durkos came into this world, she let out a gutsy cry.
“It was music to our ears,” says her mom.
Michelle Carino Durkos was 40 weeks pregnant when she learned there was a tumor attached to her unborn daughter’s heart — a tumor so large that doctors near her home in Pensacola, Florida, were unsure if the baby would live.
“It was a shock, because at 20 weeks everything was normal,” says Michelle. “We had a wonderful ultrasound; we saw all four chambers.”
Yet, call it a mother’s intuition, Michelle knew something wa...
Source: Thrive, Children's Hospital Boston - February 1, 2017 Category: Pediatrics Authors: Emily Williams Tags: Our Patients’ Stories cardiac fibroma cardiac tumor Department of Cardiac Surgery Department of Cardiology Dr. Pedro del Nido Dr. Tal Geva echocardiogram ECMO Fetal Cardiology Program heart tumor neona ultrasound Source Type: news
BioSig seeks funding in the EU
BioSig Technologies (OTCQB: BSGM) said today it will engage in an institutional investor roadshow in the EU as it seeks funding for its proprietary Pure electrophysiology platform.
The company is developing a cardiac signal acquisition and display system which is designed to assist electrophysiologists in making clinical decisions for patients with abnormal heart rates and rhythms, including atrial fibrillation and ventricular tachycardia.
Minneapolis, Minn.-based BioSig said it will tour “major EU financial centers” between Feb. 27 and March 3, with board chair Kenneth Londoner delivering presentations and m...
Source: Mass Device - January 30, 2017 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Cardiovascular BioSig Technologies Source Type: news
Thermedical raises $3m for tissue ablation device
Thermedical raised $3 million in a new round of funding, according to regulatory filings. The private company is developing a treatment for ventricular tachycardia, an irregular heartbeat that can result in sudden cardiac arrest, and a treatment for soft tissue conditions, including liver, kidney, lung and uterine tumors.
The company’s ablation system uses saline-enhanced radio frequency, according to Thermedical, to overcome the challenges of traditional ablation tools and to create large, controlled, symmetrical lesions.
The new round, which had its 1st sale on Jan. 13, will bring $700,000 to the company for gene...
Source: Mass Device - January 25, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Cardiovascular Funding Roundup Thermedical Source Type: news
Clinical trial testing new technique to treat life-threatening ventricular tachycardia
A landmark clinical trial is evaluating a new procedure to treat a life-threatening heart rhythm disorder called ventricular tachycardia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 23, 2017 Category: Science Source Type: news
